The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2023 | The role of NICE in the UK for lung cancer
Tom Newsom-Davis, BSc, MBBS, PhD, FRCP, Chelsea and Westminster Hospital, London, UK, comments on the presentation about the National Institute for Health and Care Excellence (NICE) given at Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK. He touches upon expenditure, challenges in the industry, and what positive NICE approval has looked like historically in the lung cancer space. This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Received support to attend educational conferences from AstraZeneca, BMS, Boeringher Ingelheim, Lilly, MSD, Otsuka, Roche and Takeda. Consulting fees from Amgen, AstraZeneza, Bayer, BMS, Boeringher Ingelheim, EQRx, GSK, Guardant, Janssen, Lilly, Merck, MSD, Novartis, Otsuka, Pfizer, Roche, Sanofi and Takeda. Clinical Trial Steering Committee for Roche. Speaker bureaus for AstraZeneza, Pfizer, Roche, MSD and Takeda.
